Stay updated with breaking news from Sonnet Founder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ...
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN)Rece...
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual ...
Sonnet BioTherapeutics Holdings, Inc. , a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take...